Form D · Biotechnology

Gemin X Pharmaceuticals Inc

Malvern, PA · CIK 0001407168

Offering snapshot reported May 14, 2010 · SEC filing

Reported sold
$3.92M
Offering amount: $8.5M
Investors reported
16
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
May 7, 2010
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
May 14, 2010Initial$3,916,229No comparison16SEC filing
Jun 12, 2009Initial$9,259,078No comparison24SEC filing
Jul 16, 2007PaperNot reportedNo comparisonNot reportedSEC filing
Jul 16, 2007PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-142104

Source: Form D, filed May 14, 2010. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Timothy J. Barberich Director
Aaron Davidson Director
D. Michael Dixon Executive
Peter R. Dolan Director, Executive
Robert Gorman Director
Andrew R. Jordan Director
Robert G. Mc Neil Director
Scott Morenstein Director
Eric W. Roberts Director
Gordon C. Shore Director, Executive
Jean Viallet Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
400 Chesterfield Parkway Suite 100
Malvern, PA, 19355